In 2002, U.S. Food and Drug Administration staff scientists called for reports of congestive heart failure to be included on the label of Avandia as well as Actos, made by Takeda Pharmaceutical Co. Ltd., the group said, citing an internal FDA document.
The group released the memo one day after researchers reported Avandia, or rosiglitazone, raises the risk of other heart-related problems -- cardiovascular-related death by 64 percent and heart attack by 43 percent.
For more of the story: http://www.reuters.com/article/healthNews/idUSN2246284520070522